|
Aug 5
|
Invitation to the presentation of Calliditas´s interim report January - June 2024
|
|
Jul 26
|
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
|
|
Jul 26
|
Calliditas’ Phase IIb trial of PBC treatment meets primary endpoint
|
|
Jul 26
|
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
|
|
Jun 17
|
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
|
|
May 15
|
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
|
|
May 15
|
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
|
|
May 15
|
Exploring Three Swedish Growth Companies With High Insider Ownership On The Swedish Exchange
|
|
May 14
|
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
|
|
May 6
|
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
|
|
May 2
|
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
|
|
Apr 24
|
Calliditas Therapeutics' 2023 Annual Report Published
|
|
Apr 24
|
Calliditas Announces Positive NefIgArd Open Label Extension Results
|
|
Apr 18
|
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
|
|
Apr 16
|
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
|
|
Apr 9
|
Calliditas Therapeutics to Attend Conferences in April
|
|
Apr 8
|
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
|
|
Apr 8
|
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
|
|
Mar 12
|
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
|
|
Mar 6
|
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
|